CD274 and small cell lung carcinoma: More recently, two randomized phase III trials (IMpower133 and CASPIAN) indicated that anti‐programmed cell death ligand 1(PD‐L1) therapy (atezolizumab or durvalumab) significantly improved OS with a tolerable safety profile in patients with ES‐SCLC.9, 10, 11